BioPharm International, February 2013 Issue (PDF)
Viral Vaccines
Assessing Development Needs for Biobetters and Biosimilars
Development requirements and regulatory guidance for biosimilars and biobetters.
Facility Design and Operation: A Primer
NIBRT's Michael Lacey provides an overview of biopharmaceutical facility design and operation.
Offering a Biopharma View of Social Media
Ever since Twitter launched in 2006 and Facebook became mainstream, most industries have sought ways to connect with their consumers through social media.
GMP Compliance Becomes Prominent Enforcement Issue
Shortages spur efforts to overhaul manufacturing oversight.
Therapeutic Antibodies in Review
Innovative products and a range of indications drive the therapeutic antibody market.
The Vaccine Scene
A look at vaccine history, markets, manufacturing, and overcoming the scale-up dilemma.
Automated Concentration and Diafiltration of Multiple siRNA Samples
Project: transfer a manual concentration/diafiltration process for siRNA production.
End of the Dedicated CMO?
Is the contract-only CMO an endangered species?
Viral Vaccine Manufacturing
Tony Hitchcock of Cobra Biologics discusses challenges posed by production of viral vectors for vaccines.
Navigating Emerging Markets: Eastern Europe
Eastern Europe is moving towards a goal of harmonized regulations.
India's Biopharma Industry Valued at $2 Billion
India's biopharmaceutical industry is valued at $2 billion a year with 20 companies producing biosimilars and 50 products available in the domestic market.
Relevance Regained
Improvement strategy should be linked to business strategy.
